E. coli, K. pneumoniae and K. oxytoca community-acquired infections susceptibility to cephalosporins and other antimicrobials in Lebanon.

OBJECTIVES Cephalosporin resistance in Enterobacteriaceae has become an international concern. This article studies the distribution and trends of resistance of E. coli and Klebsiella species isolated from clinical specimens representing community-acquired infections. METHODS E. coli, K. pneumoniae and K. oxytoca specimen strains were collected from patients presenting to three acute care hospitals in Lebanon. The study period extended from January 2010 to January 2011 and included patients presenting with community-acquired infections only. Automated microbiological system (VITEK 2) was used for identification and antimicrobial susceptibilities. RESULTS Data from consecutive non-duplicate 589 E. coli, 54 K. pneumoniae and 40 K. oxytoca strains were collected of which 69.5%, 74.0% and 67.5% were susceptible to 3rd generation cephalosporins (3GC), respectively. Out of the 3GC-resistant E. coli strains, around 90% were susceptible to nitrofurantoin, 46% were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX) and 53% to ciprofloxacin. The patterns of antimicrobial susceptibility in the two Klebsiella species did not parallel those in the E. coli strains. Yet, the number of Klebsiella strains was much lower than that of E. coli. Of note is that the 3GC-resistant strains of both Klebsiella species were less susceptible to nitrofurantoin compared to the overall groups reaching a maximum of 30%. However, susceptibility to TMP/SMX was much higher reaching 79% and that of ciprofloxacin reaching 86%. CONCLUSION Clinical specimens of E. coli, Klebsiella pneumoniae and Klebsiella oxytoca, causing community-acquired infections in Lebanon showed that these organisms are significantly resistant to many antibiotics. These patterns of resistance were mainly to internationally recommended drugs for empiric treatment of community-acquired infections like community-acquired urinary tract infections (UTIs) and intra-abdominal infections. Therefore, continuous antimicrobial susceptibility surveillance is advisable to track emerging resistance in Enterobacteriaceae and national guidelines would be tailored accordingly.

[1]  S. Pournaras,et al.  Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria. , 2013, International journal of antimicrobial agents.

[2]  G. Araj,et al.  A reflection on bacterial resistance to antimicrobial agents at a major tertiary care center in Lebanon over a decade. , 2012, Le Journal medical libanais. The Lebanese medical journal.

[3]  G. Araj,et al.  In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. , 2012, Le Journal medical libanais. The Lebanese medical journal.

[4]  D. Sarkis,et al.  [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009]. , 2012, Pathologie-biologie.

[5]  W. Sweileh,et al.  Antibiotic resistance of bacterial strains isolated from patients with community-acquired urinary tract infections: an exploratory study in Palestine. , 2011, Current Clinical Pharmacology.

[6]  J. Shin,et al.  Prevalence of Plasmid-mediated Quinolone Resistance and Its Association with Extended-spectrum Beta-lactamase and AmpC Beta-lactamase in Enterobacteriaceae , 2011, The Korean journal of laboratory medicine.

[7]  S. H. Teo,et al.  Aetiology of community-acquired urinary tract infection and antimicrobial susceptibility patterns of uropathogens isolated. , 2011, Singapore medical journal.

[8]  Richard Colgan,et al.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Luis Martõ Plasmid-mediated quinolone resistance: an update , 2011 .

[10]  A. Corso,et al.  Can We Use Imipenem and Meropenem Vitek 2 MICs for Detection of Suspected KPC and Other-Carbapenemase Producers among Species of Enterobacteriaceae? , 2010, Journal of Clinical Microbiology.

[11]  P. Nordmann,et al.  Spread of OXA-48-mediated resistance to carbapenems in Lebanese Klebsiella pneumoniae and Escherichia coli that produce extended spectrum β-lactamase , 2010, Annals of tropical medicine and parasitology.

[12]  H. Rajak,et al.  Fluoroquinolones in urinary tract infections: A stu dy on perception analysis of prescribers , 2010 .

[13]  P. Edelstein,et al.  Specificity of Ertapenem Susceptibility Screening for Detection of Klebsiella pneumoniae Carbapenemases , 2009, Journal of Clinical Microbiology.

[14]  M. Dettenkofer,et al.  Should We Screen Patients for Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae in Intensive Care Units? , 2009, Infection Control & Hospital Epidemiology.

[15]  G. Gerken,et al.  [Collateral damage of cephalosporins and quinolones and possibilities for control]. , 2009, Medizinische Klinik.

[16]  J. Ayala-Gaytán,et al.  [Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections. What antimicrobial to use?]. , 2009, Salud publica de Mexico.

[17]  D. Livermore,et al.  Plasmids Imparting Sulfonamide Resistance in Escherichia coli: Implications for Persistence , 2008, Antimicrobial Agents and Chemotherapy.

[18]  G. Araj,et al.  Tigecycline in vitro activity against commonly encountered multidrug-resistant gram-negative pathogens in a Middle Eastern country. , 2008, Diagnostic microbiology and infectious disease.

[19]  Atul Kothari,et al.  Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. , 2008, Journal of infection in developing countries.

[20]  A. Oliver,et al.  Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. , 2008, Archives of internal medicine.

[21]  Y. Carmeli,et al.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. , 2007, The Journal of antimicrobial chemotherapy.

[22]  J. Morris,et al.  Risk Factors for Colonization with Extended-Spectrum β-Lactamase–producing Bacteria and Intensive Care Unit Admission , 2007, Emerging infectious diseases.

[23]  R. Theriault,et al.  Once daily, oral, outpatient quinolone monotherapy for low‐risk cancer patients with fever and neutropenia , 2006, Cancer.

[24]  Z. Daoud,et al.  Extended spectrum beta-lactamase producing Enterobacteriaceae in Lebanese ICU patients: epidemiology and patterns of resistance. , 2006, The Journal of general and applied microbiology.

[25]  D. Livermore,et al.  Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. , 2005, The Journal of antimicrobial chemotherapy.

[26]  Robert A. Bonomo,et al.  Extended-Spectrum (cid:2) -Lactamases: a Clinical Update , 2005 .

[27]  L. Nicolle,et al.  Complicated urinary tract infection in adults. , 2005, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[28]  A. Madan Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections. , 2004, Clinical therapeutics.

[29]  J. Rodríguez-Baño,et al.  Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Nonhospitalized Patients , 2004, Journal of Clinical Microbiology.

[30]  M. Schaller,et al.  Cefepime versus Imipenem-Cilastatin for Treatment of Nosocomial Pneumonia in Intensive Care Unit Patients: a Multicenter, Evaluator-Blind, Prospective, Randomized Study , 2003, Antimicrobial Agents and Chemotherapy.

[31]  Z. Daoud,et al.  [Prevalence and susceptibility patterns of extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae in a general university hospital in Beirut, Lebanon]. , 2003, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[32]  D. Paterson Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  D. Livermore beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.

[34]  J. D. Conklin The pharmacokinetics of nitrofurantoin and its related bioavailability. , 1978, Antibiotics and chemotherapy.